The inhibitor-of-apoptosis (IAP) proteins are a novel family of antiapoptotic proteins that are thought to inhibit cell death via direct inhibition of caspases. Here, we report that human malignant glioma cell lines express XIAP, HIAP-1 and HIAP-2 mRNA and proteins. NAIP was not expressed. IAP proteins were not cleaved during CD95 ligand (CD95L)-induced apoptosis, and loss of IAP protein expression was not responsible for the potentiation of CD95L-induced apoptosis when protein synthesis was inhibited. LN-18 cells are highly sensitive to CD95-mediated apoptosis, whereas LN-229 cells require co-exposure to CD95L and a protein synthesis inhibitor, CHX, to acquire sensitivity to apoptosis. Adenoviral XIAP gene transfer blocked caspase 8 and 3 processing in both cell lines in the absence of CHX. Apoptosis was blocked in the absence and in the presence of CHX. However, XIAP failed to block caspase 8 processing in LN-229 cells in the presence of CHX. There was considerable overlap of the effects of XIAP on caspase processing with those of BCL-2 and the viral caspase inhibitor crm-A. These data define complex regulatory mechanisms for CD95-mediated apoptosis in glioma cells and indicate that there may be a distinct pathway of death receptor-mediated apoptosis that is readily activated when protein synthesis is inhibited. The constitutive expression of natural caspase inhibitors may play a role in the resistance of these cells to apoptotic stimuli that directly target caspases, including radiochemotherapy and immunemediated tumor cell lysis.
Introduction
Human malignant glioma cells are paradigmatic for their intrinsic resistance to multiple proapoptotic stimuli. The molceular basis of their resistance to apoptosis has not been fully elucidated. Several viruses have been shown to express inhibitors of apoptotic cell death which are thought to inhibit the death of infected cells while the virus is replicating. 1 Some of these proteins, e.g., the adenoviral E1B protein and the Epstein Barr virus protein BHRF-1 (BCL-2 homologue open reading frame-1), may resemble the mammalian BCL-2 protein.
2 BCL-2 inhibits apoptosis, amongst others, by preventing the release of cytochrome C from mitochondria which in turn would activate caspases. 3, 4 Other antiapoptotic factors such as the baculoviral p35 protein appear to have no structural mammalian counterpart. p35 acts via competitive inhibition of caspases. 5 Another family of inhibitor-ofapoptosis proteins (IAP) has also been identified in baculoviruses. 6 Neuronal apoptosis-inhibitory protein (NAIP), a gene linked to spinal muscle atrophy, was the first human gene identified that showed sequence homology to genes coding for the viral IAP proteins. 7 The NAIP protein is widely expressed in neurons in the rat central nervous system but not in glial cells in vivo. 8 At least three further IAP genes with antiapoptotic properties were subsequently identified: HIAP-1, HIAP-2 and XIAP. 9 ± 11 Forced expression of NAIP inhibited cell death induced by serum deprivation or menadione in CHO cells and TNF/CHX-induced apoptosis in HeLa cells. The three novel mammalian IAP proteins inhibited cell death induced by serum deprivation or menadione but not staurosporine-induced apoptosis. Further, adenoviral NAIP gene transfer reduced ischaemic neuron loss in the hippocampus. 12 XIAP, HIAP-1 and HIAP-2, but not NAIP, interfere with apoptosis at the level of caspase 3 and 7 processing. 13, 14 Further, these proteins have been shown to interact directly with reaper, a death-inducing protein in Drosophila.
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The same inhibitors of apoptosis were independently cloned by Vaux and colleagues 11 who referred to these genes as MIHA (XIAP), MIHB (HIAPII) and MIHC (HIAPI). MIHA and MIHB, but not MIHC, inhibited apoptosis mediated by ectopic expression of caspase 1 in HeLa cells. Neither MIHA nor MIHB nor MIHC inhibited cell death induced by ectopic expression of FADD (Fasassociating protein with death domain) which forms part of the death-inducing signalling complex (DISC) of CD95-mediated apoptosis. 16 Further, MIHB and MIHC were shown to interact with TRAF-1 and TRAF-2 (TNF receptor-associated factor) in the yeast two-hybrid system. 11 TRAF-1 and TRAF-2 are involved in survivalpromoting rather than cytotoxic signalling mediated by TNF receptors. 17 Consistent with a role of nuclear factor (NF)-kB in TNF-induced stimulation or activation rather than TNF-induced cell death, the IAP-mediated protection from TNF cytotoxicity has been hypothesized to be Cell Death and Differentiation (1999) 6, 370 ± 376 controlled by NF-kB. 18, 19 Survivin, a human gene encoding a new apoptosis inhibitor with structural similarity to IAP, was recently identified. 20 Survivin is unique in that it is expressed selectively in most common human cancers but not in normal adult tissue. 21 Expression of the antiapoptotic survivin seems to correlate with an histologically more aggressive type and an unfavourable prognosis of neuroblastoma. 22 Here, we have examined the expression and functional activity of IAP family proteins in human malignant glioma cells.
Results

Expression of IAP family genes in human malignant glioma cell lines
Total RNA from the 12 glioma cell lines was examined for the expression of IAP family genes by RT ± PCR ( Figure 1A , Table 1 ). XIAP, HIAP-1 and HIAP-2 mRNA were detected in all cell lines. At the protein level, XIAP, HIAP-1 and HIAP-2 were also detected in all cell lines ( Figure 1B) . Although the antibodies to HIAP-1 and HIAP-2 yielded a high background, adenoviral gene transfer of the respective IAP genes indicated which bands corresponded to the protein of interest. In contrast, NAIP protein was not detected in any of the cell lines using adenoviral NAIP gene transfer as a positive control (data not shown).
IAP family proteins are not the target of CHXdependent potentiation of CD95L-induced apoptosis of human glioma cells
Since IAP are thought to inhibit apoptosis via direct inhibition of caspases 13, 14, 23 and since caspase activation is required for CD95L-induced apoptosis of malignant glioma cells, 24, 25 we next examined the role of endogenous IAP in the apoptotic cell death of CD95L-treated LN-18 and LN-229 cells. First, we wished to examine whether IAP are potential targets for proteolytic degradation during apoptosis. These experiments were performed because, e,g., the antiapoptotic BCL-2 protein has been shown to undergo caspasedependent proteolysis during apoptosis. 26 We find that IAP are not cleaved as a result of CD95L-induced caspase activation ( Figure 2A) . In parallel experiments, we confirmed that PKCd, a known substrate for caspases, was cleaved under these conditions ( Figure 2A) . Moreover, we have demonstrated earlier that cleavage of caspases 8 and 3 as well as poly-(ADP)-polymerase started 3 ± 4 h after CD95 stimulation of LN-18 and LN-229 cells. 25 Potentiation by inhibitors of RNA and protein synthesis such as ActD or CHX is a typical feature of CD95L-induced apoptosis 27 ( Figure 2B and C). This has been explained by the presence of cytoprotective proteins which are short-lived and therefore deficient when glioma cells are killed by CD95L under conditions of inhibited protein synthesis. To assess whether IAP represent these hitherto unidentified putative cytoprotective proteins, we monitored the levels of IAP after exposure of the glioma cells to CHX. Figure 2D shows that the levels of XIAP remain stable within the time frame of the experiments, suggesting that a rapid loss of IAP does not mediate CHX-induced sensitization of glioma cells to CD95L-induced apoptosis. Similar results were observed with the putative HIAP-1 and HIAP-2 proteins (data not shown). Figure 3A) . Note that transgene expression at the protein level was unaffected by CHX within the time frame of the experiment, consistent with Figure 2D . In earlier studies, 25 we have shown that CD95L induced caspase 8 and caspase 3 processing in glioma cells at 4 h of treatment. Since IAP proteins are inhibitors of caspases, specifically of caspase 3, 14 we next asked whether XIAP inhibited the proteolytic cleavage of caspases 8 and 3 after CD95 triggering.
Adenoviral XIAP gene transfer
In the absence of CHX, ectopic expression of XIAP inhibited the cleavage of both caspases 8 and caspase 3 when the glioma cells were exposed to CD95L (Figure 3B and C; left panels). Specifically, p18/caspase 8 was not detectable in XIAP-transduced cells, and p17/caspase 3 formation was blocked. In the presence of CHX, caspase 8 cleavage was greatly attenuated in LN-18 cells but largely unaffected in LN-229 cells. In contrast, CD95L-evoked caspase 3 cleavage to a p17 fragment was still prevented by XIAP in both cell lines. Interestingly, formation of the inactive p20/caspase 3 fragment was not detectable in LN-18 cells but only in LN-229 cells. As previously reported, 30 ectopic expression of XIAP promoted the accumulation of p20/caspase 3, as a consequence of inhibition of autoprocessing.
Next, we analyzed caspase 3-like activity by measuring the cleavage of the fluorigenic substrate, Ac-DEVD-AMC. Ectopic expression of XIAP blocked DEVD-specific caspase activity ( Figure 4A and B) and conferred strong protection from CD95-mediated cell death ( Figure 4C 
Discussion
CD95L-induced apoptosis is a promising strategy of cytokine therapy for malignant glioma. 24 The IAP proteins constitute a novel family of antiapoptotic proteins which are currently explored for their possible role in development and during cancerogenesis. Here, we report that XIAP, HIAP-1 and HIAP-2 are widely expressed by glioma cell lines (Figure 1) , suggesting that these proteins may play a role in the striking resistance of gliomas to the induction of apoptosis by radiotherapy and cancer chemotherapy. In contrast, NAIP was not expressed by glioma cells. The lack of NAIP expression in glioma cell lines in vitro is consistent with strictly neuronal NAIP expression in the rat brain in vivo. 8 Next, we examined the role of IAP proteins in CD95-mediated apoptosis of two human malignant glioma cell lines, LN-18 and LN-229. These cell lines differ in their requirement for concurrent inhibition of protein synthesis for the CD95L to induce apoptosis. 27 LN-18 cells are highly sensitive to CD95L whereas LN-229 cells require coexposure to CD95L and an inhibitor of protein synthesis, CHX, to efficiently undergo apoptosis ( Figure 2B and C) . The strong potentiation of CD95-mediated apoptosis by CHX indicates the constitutive expression of antiapoptotic proteins which normally interfere with transduction of an apoptotic signal after CD95 triggering. Figure 2D shows that IAP proteins are not identical to these unknown proteins since their levels of expression do not rapidly decline after exposure to CHX.
Caspase-dependent proteolysis of various substrates has been shown to play an important role in CD95-mediated apoptosis in all cell types examined so far, 28, 29 including glioma cells. 25 Here, we show that XIAP is not a substrate for caspase-dependent proteolysis under conditions where caspases 8, 3, PKCd and PARP are processed (Figure 2A ). 25 Scaffidi and colleagues 16 have delineated two types of CD95-dependent killing cascades where the amount of active caspase 8 generated at the death-inducing signalling complex (DISC) determines whether a mitochondriaindependent pathway (type I cells) or a mitochondriadependent pathway (type II cells) is used. Type 1 death involves sequential activation of caspase 8 and 3 and is not blocked by bcl-2 whereas type II death requires a mitochondrial step, most likely cytochrome c release, prior to caspase activation and is blocked by BCL-2. Based on the protective effect of BCL-2 and the parallel rather than sequential activation of caspases 8 and 3, 25 glioma cells would be classified as type II cells.
The inhibition of both caspase 8 and caspase 3 processing by XIAP in the absence of CHX would be consistent with the presence of an upstream caspase activity amenable to inhibition by XIAP, e.g., caspase 9, which cleaves both caspases 8 and 3, for the following reasons: (i) XIAP prevents caspase 8 processing (Figure 3 ) but does not directly interact with caspase 8 13, 30 and (ii) caspase 8 is not known to be cleaved by caspase 3. This hypothesis is in line with a mitochondrial step in a type II CD95-mediated death of glioma cells 16 and with the putative role for caspase 9 in triggering mitochondrial cytochrome c release. 31 When protein synthesis was inhibited, XIAP still prevented caspase 3 processing in both cell lines but was no more able to inhibit caspase 8 processing in LN-229 cells ( Figure 3B ). There was good correlation between the ability of XIAP to inhibit caspase 3 processing ( Figure  3C ), DEVD-cleaving caspase activity ( Figure 4A and B) and cell death ( Figure 4C and D) , suggesting that caspase 3, once activated, may be the key executioner of CD95-mediated apoptosis in glioma cells. The protective effect of XIAP in the presence of CHX could thus fully rely on the ability of XIAP to block caspase 3 processing. In contrast, caspase 8 processing per se is not sufficient to kill LN-229 cells after exposure to CD95L and CHX, confirming the role of caspase 8 as a signalling caspase rather than killing caspase in this cell line.
We have shown that the viral caspase inhibitor, crm-A, inhibits the formation of p18/caspase 8 in both cell lines, the formation of p20/caspase 3 in LN-229 cells, and of p17/ caspase 3 in both cell lines, even in the presence of CHX, 2 5 consistent with direction of caspase 8 (auto)processing by crm-A. BCL-2 inhibits the formation of p18/caspase 8 as well as crm-A. However, unlike crm-A, BCL-2 does not block the formation of p20/caspase 3 in LN-229 cells in the presence of CHX, but rather acts like XIAP, be it direct or indirect, to inhibit caspase 3 autoprocessing. 25 Importantly, in the presence of CHX, caspase 8 cannot be the only mediator of caspase 3 processing, since BCL-2 blocks caspase 8 processing but not the initial cleavage of caspase 3 to p20 in LN-229 cells co-exposed to CD95L and CHX. 25 XIAP inhibits the formation of p18/caspase 8 in LN-18 cells in the absence and presence of CHX but not in LN-229 cells in the presence of CHX. Taken together, these data indicate a partial functional overlap of the protective effects of crm-A, bcl-2 and XIAP from CD95L-induced apoptosis in glioma cells and suggest the presence of a distinct pathway of death receptor-mediated apoptosis that is facilitated when protein synthesis is inhibited.
Materials and Methods
Cell lines
LN-18, U138MG, U87MG, LN-428, D247MG, T98G, LN-319, LN-229, A172, U251MG, U373MG and LN-308 human malignant glioma cells were kindly provided by Dr. N. de Tribolet (Laussanne, Switzerland). The cells were maintained in DMEM containing 10% foetal calf serum, 2 mM glutamine and antibiotics. 27, 32, 33 LN-18 and LN-229 cells expressing crm-A and puro control cell lines have been described. 25 
RT ± PCR
RNA was prepared by the RNeasy Mini kit from Quiagen according to a standard protocol. RT ± PCR was performed according to standard procedures as outlined previously, 33 except that random primers were used instead of oligo (dT) 30 for first strand cDNA synthesis. A nested PCR protocol was used for the detection of HIAP-1 mRNA. Primer sequences and amplification conditions are summarized in Table 1 . No signal was obtained when RT was omitted from the RT reaction.
Immunoblot analysis
Soluble protein lysates were obtained from subconfluent glioma cell cultures and SDS ± PAGE with electroblotting performed as described. 27 The following polyclonal antibodies were raised in rabbits: anti-human XIAP; anti-rat IAP (RIAP)-1, cross-reactive with HIAP-1; anti-RIAP-2, cross-reactive with HIAP-2; and anti-mouse NAIP. The caspase 8 antibody C15 (mouse monoclonal) was kindly provided by P.H. Krammer (Heidelberg, Germany). The caspase 3 antibody (mouse monoclonal) was obtained from Transduction Laboratories (Lexington, KY, USA). The PKCd antibody (rabbit polyclonal) was obtained from Santacruz (Santa Cruz, CA, USA). The secondary antibodies, protein A and anti-mouse IgG, were purchased from Amersham (Braunschweig, Germany). Enhanced chemiluminescence (ECL, Amersham) was used for detection.
Adenoviral gene transfer
Adenoviral vectors were generated using the previously described open reading frames for XIAP. HIAP-1 and HIAP-2. The open reading frames of the adenovirus vectors were sequenced to make sure that no inactivating mutations had occurred. Subconfluent cultures of LN-18 or LN-229 cells were infected with supernatant of recombinant adenoviruses at a multiplicity of infection (MOI) of 50. The cells were exposed to the infectious viral particles in medium without serum for 30 min. Then, full medium was added for 16 h. In AdV-LacZ infected cells, b-galactosidase activity was measured as described previously. 34 
Caspase 3-like enzymatic activity
The cells were seeded in 96 well plates (10 000 cells per well) and allowed to attach for 24 h. Then the cells were infected with AdV-XIAP as described above using lacZ-expressing adenovirus as control. At 16 h after infection, the cells were treated as indicated for 6 h. The cells were lysed in buffer (25 mM Tris/HCl pH 8.0, 60 mM NaCl, 2.5 mM eDTA, 0.25% NP40) for 10 min and then the substrate, acetylAsp-Glu-Val-Asp-chloromethylcoumarin (Ac-DEVD-AMC; 12.5 mM), diluted in PBS, added and incubated at 378C for 10 min. Caspase 3-like activity was measured for 1 h using a CytoFluor 2350 Millipore fluorometer at 360 nm excitation and 480 nm emission wave lengths.
Viability assay
Glioma cell viability was measured by crystal violet staining. 27 Briefly, the cell culture medium was removed and surviving cells stained with 0.5% crystal violet in 20% methanol for 20 min at room temperature. The plates were washed extensively under running tap water, air-dried and optical density values read in an ELISA reader at 550 nm wave length.
